Ladenburg -
The detailed form of the financing will be decided by the management and supervisory boards of
With this additional commitment, the Company's cash reach is secured until mid-2021.
About
The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON and REDECTANE.
Contact:
Tel: +49 89 41 31 38-29
Email: investors[at]hdpharma.com
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will' 'should' 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
(C) 2020 Electronic News Publishing, source